7-Aug-2026
Boston Scientific, Circle, Illumina, Southern Co, Toyota Insider Frenzy
TipRanks (Sat, 8-Aug 9:01 AM ET)
Illumina Seeks Court Approval of GRAIL Settlement
TipRanks (Fri, 7-Aug 4:49 PM ET)
Illumina Rocked by Massive Insider Stock Sale From Boardroom Power Player
TipRanks (Thu, 6-Aug 10:05 PM ET)
TipRanks (Thu, 6-Aug 4:56 AM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Tue, 4-Aug 11:00 PM ET)
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
PRNewswire (Thu, 30-Jul 4:05 PM ET)
Illumina expands Billion Cell Atlas program with new AI drug developers
PRNewswire (Thu, 16-Jul 12:00 PM ET)
Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
PRNewswire (Thu, 9-Jul 4:05 PM ET)
Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
PRNewswire (Thu, 9-Jul 9:05 AM ET)
Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors
PRNewswire (Tue, 23-Jun 9:05 AM ET)
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Illumina trades on the NASDAQ stock market under the symbol ILMN.
As of August 7, 2026, ILMN stock price declined to $187.96 with 1,703,832 million shares trading.
ILMN has a beta of 1.09, meaning it tends to be more sensitive to market movements. ILMN has a correlation of 0.07 to the broad based SPY ETF.
ILMN has a market cap of $28.74 billion. This is considered a Large Cap stock.
Last quarter Illumina reported $1 billion in Revenue and $1.31 earnings per share. This beat revenue expectation by $31 million and exceeded earnings estimates by $.08.
In the last 3 years, ILMN traded as high as $207.00 and as low as $68.70.
The top ETF exchange traded funds that ILMN belongs to (by Net Assets): IJH, VTI, VB, VXF, IBB.
ILMN has outperformed the market in the last year with a return of +96.8%, while the SPY ETF gained +23.5%. In the last 3 month period, ILMN beat the market returning +35.5%, while SPY returned +6.0%. However, in the most recent 2 weeks ILMN has underperformed the stock market by returning -3.2%, while SPY returned +4.6%.
ILMN support price is $188.35 and resistance is $199.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ILMN shares will trade within this expected range on the day.